98
Participants
Start Date
June 30, 2014
Primary Completion Date
August 31, 2017
Study Completion Date
January 31, 2019
Escitalopram 20mg for 2 weeks
30 cognitively normal adults aged 60-85 will receive escitalopram 20 mg for 2 weeks; amyloid beta levels in the CSF will be measured at baseline (before drug administration) and following the full study drug (i.e., active drug) administration.
Escitalopram 20mg for 8 weeks
30 cognitively normal adults aged 60-85 will receive escitalopram 20 mg for 8 weeks; amyloid beta levels in the CSF will be measured at baseline (before drug administration) and following the full study drug (i.e., active drug) administration.
Escitalopram 30mg for 8 weeks
30 cognitively normal adults aged 60-85 will receive escitalopram 30 mg for 8 weeks; amyloid beta levels in the CSF will be measured at baseline (before drug administration) and following the full study drug (i.e., active drug) administration.
Placebo
Additionally, 30 cognitively normal adults aged 60-85 will receive a placebo; amyloid beta levels in the CSF will be measured at baseline (before drug administration) and following the full study drug (i.e., placebo) administration.
University of Pennsylvania, Philadelphia
Washington University, St Louis
Washington University School of Medicine
OTHER
University of Pennsylvania
OTHER